TNYA (Tenaya Therapeutics) NonCurrent Deferred Liabilities: $3.94 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TNYA Tenaya Therapeutics Inc TNYA
32 GF Score
Price $0.71
! 4 Warning Signs
View Full Analysis

What is Tenaya Therapeutics NonCurrent Deferred Liabilities?

Tenaya Therapeutics TNYA -2.25% 32 NonCurrent Deferred Liabilities is $3.94 Mil as of Jun. 2026. GuruFocus rates TNYA with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Tenaya Therapeutics's non-current deferred liabilities for the quarter that ended in Jun. 2026 was $3.94 Mil.

Tenaya Therapeutics NonCurrent Deferred Liabilities Related Terms

Tenaya Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for Tenaya Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tenaya Therapeutics NonCurrent Deferred Liabilities Chart

Tenaya Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Tenaya Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 4.68 3.94
TNYA
32GF Score
Tenaya Therapeutics Inc TNYA
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $3.94 Mil mean?
Tenaya Therapeutics (TNYA) has a NonCurrent Deferred Liabilities of $3.94 Mil as of Jun. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Tenaya Therapeutics and its competitors.
Is Tenaya Therapeutics' NonCurrent Deferred Liabilities too high?
Tenaya Therapeutics' current NonCurrent Deferred Liabilities is $3.94 Mil. Overall, Tenaya Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' NonCurrent Deferred Liabilities compare to KPTI and HUMA?
Tenaya Therapeutics' NonCurrent Deferred Liabilities of $3.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on Tenaya Therapeutics and its competitors. Tenaya Therapeutics's current NonCurrent Deferred Liabilities is $3.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current NonCurrent Deferred Liabilities of $3.94 Mil. The current NonCurrent Deferred Liabilities is $3.94 Mil. Tenaya Therapeutics' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current NonCurrent Deferred Liabilities is $3.94 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Tenaya Therapeutics Business Description

Address 171 Oyster Point Boulevard, Suite 500, 5th Floor, South San Francisco, CA, USA, 94080
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
32GF Score

Get the complete analysis for TNYA

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.71
Price